Experiments have shown that this program can effectively increase the activity of the TGF-β1/Smad2 signaling pathway, significantly reduce the proliferation of liver cancer cells, and the tumor inhibition rate can reach 35%. This evidence concerns the gene TGFB1 and neoplasm.